Nykode Therapeutics ASA Cash Flow Conversion Efficiency
Nykode Therapeutics ASA cash flow conversion efficiency. Based on the latest financial reports, Nykode Therapeutics ASA (NYKD) has a cash flow conversion efficiency ratio of -0.079x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Nkr-6.35 Million ≈ $-667.99K USD) by net assets (Nkr80.39 Million ≈ $8.46 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Nykode Therapeutics ASA (2016–2025)
Cash flow conversion efficiency of Nykode Therapeutics ASA from 2016 to 2025. This chart illustrates how Nykode Therapeutics ASA's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Nykode Therapeutics ASA (NYKD) stock price for real-time trading data and today's change.
Nykode Therapeutics ASA Cash Flow Conversion Ratio Explained
Nykode Therapeutics ASA cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Nykode Therapeutics ASA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nykode Therapeutics ASA ranked by their cash flow conversion efficiency. Also see NYKD stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Atlas Salt Inc
V:SALT
|
-0.063x |
|
Donpon Precision
TWO:3290
|
0.001x |
|
Ellington Residential Mortgage
NYSE:EARN
|
0.569x |
|
Wendell Industrial Co. Ltd
TWO:6761
|
0.017x |
|
Adel Kalemcilik Ticaret ve Sanayi AS
IS:ADEL
|
-0.453x |
|
Airtel Africa Plc
LSE:AAF
|
0.286x |
|
Pioneer Floating Rate Trust
NYSE:PHD
|
0.054x |
|
OM Holdings Ltd
KLSE:5298
|
-0.004x |
Annual Cash Flow Conversion Efficiency for Nykode Therapeutics ASA (2016–2025)
The table below shows the annual cash flow conversion efficiency of Nykode Therapeutics ASA from 2016 to 2025. Review Nykode Therapeutics ASA (NYKD) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Nkr91.54 Million ≈ $9.63 Million |
Nkr-29.46 Million ≈ $-3.10 Million |
-0.322x | +14.42% |
| 2024-12-31 | Nkr136.21 Million ≈ $14.33 Million |
Nkr-51.22 Million ≈ $-5.39 Million |
-0.376x | +33.35% |
| 2023-12-31 | Nkr171.26 Million ≈ $18.02 Million |
Nkr-96.62 Million ≈ $-10.17 Million |
-0.564x | -328.11% |
| 2022-12-31 | Nkr157.02 Million ≈ $16.52 Million |
Nkr-20.69 Million ≈ $-2.18 Million |
-0.132x | -2314.20% |
| 2021-12-31 | Nkr194.06 Million ≈ $20.42 Million |
Nkr1.16 Million ≈ $121.54K |
0.006x | -99.41% |
| 2020-12-31 | Nkr178.85 Million ≈ $18.82 Million |
Nkr180.27 Million ≈ $18.97 Million |
1.008x | +365.51% |
| 2019-12-31 | Nkr242.56 Million ≈ $25.52 Million |
Nkr-92.08 Million ≈ $-9.69 Million |
-0.380x | +15.31% |
| 2018-12-31 | Nkr140.07 Million ≈ $14.74 Million |
Nkr-62.78 Million ≈ $-6.61 Million |
-0.448x | -45.30% |
| 2017-12-31 | Nkr203.53 Million ≈ $21.42 Million |
Nkr-62.78 Million ≈ $-6.61 Million |
-0.308x | -347.33% |
| 2016-12-31 | Nkr23.19 Million ≈ $2.44 Million |
Nkr-1.60 Million ≈ $-168.25K |
-0.069x | -- |
About Nykode Therapeutics ASA
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include ABI-SUVA for targeting HPV16+ induced malignancies, with head, and neck cancer as the primary indication… Read more